ifenprodil has been researched along with Cancer of Prostate in 1 studies
ifenprodil: NMDA receptor antagonist
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we reconstruct a prostate cancer (PRAD)-specific GEM for exploring prostate cancer metabolism and also repurposing new therapeutic agents that can be used in development of effective cancer treatment." | 1.51 | Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning. ( Arga, KY; Benfeitas, R; Kim, W; Mardinoglu, A; Turanli, B; Uhlen, M; Zhang, C, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turanli, B | 1 |
| Zhang, C | 1 |
| Kim, W | 1 |
| Benfeitas, R | 1 |
| Uhlen, M | 1 |
| Arga, KY | 1 |
| Mardinoglu, A | 1 |
1 other study available for ifenprodil and Cancer of Prostate
| Article | Year |
|---|---|
Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning.
Topics: Cell Line, Tumor; Cell Survival; Drug Discovery; Drug Repositioning; Gene Expression Profiling; Gene | 2019 |